Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...

The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a ... head of connected care for Lilly Diabetes. "Using the learnings from early adopters of Tempo, we look ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

Lilly is developing Tempo Smart ... "Our smart connected insulin pens aim to empower people to better understand their diabetes management, have more informed conversations with their doctor ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

Novo Nordisk, Eli Lilly & Co. and Sanofi dominate ... African and Asian countries where diabetes care is limited or expensive. Insulin pens enable accurate dosing, apart from offering better ...

A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The ...

The global drug device combination products market, valued at US$224.70 billion in 2024, stood at US$243.02 billion in 2025 ...

Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...